IBI-939
As of the edition of 20 October 2026, IBI-939 is a drug: of no established status; acts on TIGIT.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Status not established
- Kind
- Unknown
- Registered trials
- 3, 0 stopped early
- Disease areas
- Cancer
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| TIGIT | T-cell immunoreceptor with Ig and ITIM domains | Q495A1 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 3 | 3 | 0 | 0 |
| All trials | 3 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Innovent Biologics | Lead sponsor of trials | 2020 to now |